NEW YORK, Oct. 12, 2017 /PRNewswire/ --
SummaryCommunity acquired pneumonia refers to pneumonia contracted by a person who has had little contact with the healthcare system. There are a total of 20 products in development for this indication, by 17 companies. Key companies operating in this pipeline space include TaiGen Biotechnology and Merck.Read the full report: https://www.reportlinker.com/p05142593Hospital acquired pneumonia refers to any pneumonia contracted by a patient in a hospital at least 48-72 hours after being admitted, usually caused by a bacterial infection. There are a total of 39 products in development for this indication, by 29 companies. Key companies operating in this pipeline space include Aridis Pharmaceuticals, Wockhardt, AstraZeneca and Merck.Finally, Ventilator-associated pneumonia is characterized by age-related hyperplasia of the prostate gland (with or without glandular enlargement), lower urinary tract symptoms and bladder flow obstruction. There are a total of 34 products in development for this indication, by 27 companies. Key companies operating in this pipeline space include Aridis Pharmaceuticals, AstraZeneca, Merck and Polyphor.The most common targets within community acquired pneumonia are DNA gyrase, DNA topoisomerase and ribosomal RNA, common targets of antibiotics. Hospital acquired and ventilator associated pneumonia share many of the same targets and are most frequently targeted towards beta lactamase and ribosomal RNA, also common targets of antibiotic treatments and closely reflecting the current treatment landscape of these diseases.The report,"Pneumonia Drug Development Pipeline Review, 2017" provides an overview of the pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Community Acquired Pneumonia, Hospital Acquired Pneumonia and Ventilator Associated Pneumonia and features dormant and discontinued projects.Scope- Which companies are the most active within the pipeline for pneumonia therapeutics?- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?- What are the most important R&D milestones and data publications to have happened in the field of pneumonia?Reasons to buy- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administrationRead the full report: https://www.reportlinker.com/p05142593 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. https://www.reportlinker.com __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
Advertisement
SummaryCommunity acquired pneumonia refers to pneumonia contracted by a person who has had little contact with the healthcare system. There are a total of 20 products in development for this indication, by 17 companies. Key companies operating in this pipeline space include TaiGen Biotechnology and Merck.Read the full report: https://www.reportlinker.com/p05142593Hospital acquired pneumonia refers to any pneumonia contracted by a patient in a hospital at least 48-72 hours after being admitted, usually caused by a bacterial infection. There are a total of 39 products in development for this indication, by 29 companies. Key companies operating in this pipeline space include Aridis Pharmaceuticals, Wockhardt, AstraZeneca and Merck.Finally, Ventilator-associated pneumonia is characterized by age-related hyperplasia of the prostate gland (with or without glandular enlargement), lower urinary tract symptoms and bladder flow obstruction. There are a total of 34 products in development for this indication, by 27 companies. Key companies operating in this pipeline space include Aridis Pharmaceuticals, AstraZeneca, Merck and Polyphor.The most common targets within community acquired pneumonia are DNA gyrase, DNA topoisomerase and ribosomal RNA, common targets of antibiotics. Hospital acquired and ventilator associated pneumonia share many of the same targets and are most frequently targeted towards beta lactamase and ribosomal RNA, also common targets of antibiotic treatments and closely reflecting the current treatment landscape of these diseases.The report,"Pneumonia Drug Development Pipeline Review, 2017" provides an overview of the pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Community Acquired Pneumonia, Hospital Acquired Pneumonia and Ventilator Associated Pneumonia and features dormant and discontinued projects.Scope- Which companies are the most active within the pipeline for pneumonia therapeutics?- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?- What are the most important R&D milestones and data publications to have happened in the field of pneumonia?Reasons to buy- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administrationRead the full report: https://www.reportlinker.com/p05142593 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. https://www.reportlinker.com __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
View original content:http://www.prnewswire.com/news-releases/pneumonia-drug-development-pipeline-review-2017-300536182.html
SOURCE Reportlinker
